Journal Article

Effect on Hearing of Oral Valganciclovir for Asymptomatic Congenital Cytomegalovirus Infection

Dilek Yılmaz Çiftdoğan and Fadıl Vardar

in Journal of Tropical Pediatrics

Volume 57, issue 2, pages 132-134
Published in print April 2011 | ISSN: 0142-6338
Published online June 2010 | e-ISSN: 1465-3664 | DOI: http://dx.doi.org/10.1093/tropej/fmq050
Effect on Hearing of Oral Valganciclovir for Asymptomatic Congenital Cytomegalovirus Infection

Show Summary Details

Preview

Congenital cytomegalovirus (CMV) infection is the leading nongenetic cause of congenital sensorineural hearing loss (SNHL). Hearing loss due to congenital CMV infection either has onset after the newborn period or shows progressive decline in auditory thresholds. Although 90% of the congenitally infected infants are asymptomatic at birth, evidence is accumulating that these infants are at risk for audiologic, neurologic and developmental sequelae. In symptomatically infected infants, ganciclovir therapy administered in the neonatal period prevents hearing deterioration. However, preventative therapy of asymptomatic congenital CMV disease is controversial. Here in, we reported a male newborn with asymptomatic congenital CMV with bilateral SNHL. Oral treatment with valganciclovir in patient resulted in progressive improvement of SNHL, which effectively reduced the CMV viral load and was well tolerated without apparent adverse effects.

Keywords: Asymptomatic congenital cytomegalovirus infection; valganciclovir

Journal Article.  1138 words.  Illustrated.

Subjects: Paediatrics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.